☰

Megan E. Nelles, Ph.D. - Publications

Affiliations: 
2012 Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Immunology, Oncology, Medical Biophysics
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, ... ... Nelles M, et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunology, Immunotherapy : Cii. PMID 30747243 DOI: 10.1007/S00262-019-02307-X  0.465
2019 Butler MO, Saibil S, Bonilla L, Franke N, Hakgor S, Boross-Harmer S, Majeed H, Nelles M, Ohashi PS, Ross K, Sacher AG, Scheid E, Sotov V, Trang A, Vakili K, et al. Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS. Journal of Clinical Oncology. 37: 2537-2537. DOI: 10.1200/Jco.2019.37.15_Suppl.2537  0.452
2019 Butler MO, Sotov V, Saibil S, Bonilla L, Boross-Harmer S, Fyrsta M, Gray D, Nelles M, Le M, Lemiashkova D, Liu D, Sacher AG, Trang A, Vakili K, As BV, et al. Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.009  0.462
2018 Butler MO, Majeed H, Nelles M, Saibil S, Bonilla L, Boross-Harmer S, Sotov V, Elston S, Ross K, van As B, Le M, Fyrsta M, Lo C, Yam J, Nie J, et al. Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii441. PMID 32137125 DOI: 10.1093/Annonc/Mdy288.113  0.366
2015 Moreau JM, Berger A, Nelles ME, Mielnik M, Furlonger C, Cen SY, Besla R, Robbins CS, Paige CJ. Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses. Blood. 126: 1184-92. PMID 26170030 DOI: 10.1182/Blood-2015-03-635805  0.318
2015 Nelles ME, Paige CJ. CD4(+) T cell plasticity engenders robust immunity in response to cytokine therapy. Oncoimmunology. 4: e994370. PMID 25949915 DOI: 10.4161/2162402X.2014.994370  0.425
2015 Au BC, Liu Y, Huang J, Nelles M, Arruda A, Rothe M, Paul G, Schambach A, Barber DL, Minden MD, Paige CJ, Medin JA. 413. Pre-Clinical Preparation and Validation of Tumor Cell-Based IL-12 Immunotherapy for Acute Myeloid Leukemia Molecular Therapy. 23: S163. DOI: 10.1016/S1525-0016(16)34022-9  0.47
2014 Nelles ME, Moreau JM, Furlonger CL, Berger A, Medin JA, Paige CJ. Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunology Research. 2: 1113-24. PMID 25154710 DOI: 10.1158/2326-6066.Cir-13-0208  0.491
2009 Labbe A, Nelles M, Walia J, Jia L, Furlonger C, Nonaka T, Medin JA, Paige CJ. IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. Journal of Cellular and Molecular Medicine. 13: 1962-76. PMID 18624776 DOI: 10.1111/J.1582-4934.2008.00412.X  0.428
Show low-probability matches.